"In general molecular testing has been highly centralized and it needs to be decentralized into the average community hospital. These molecular diagnostic labs are highly complex, but the market would benefit from a technology that's simple and can be decentralized."

— William Moffitt, president/CEO of Nanosphere on the advantage of the company's Verigene system via its ability to move molecular diagnostics closer to patients and move infectious disease assays to point of care for more timely diagnoses, "Nanosphere submits 510(k) for rapid, POC influenza test."